Jane Street Group LLC Grows Stake in HilleVax, Inc. (NASDAQ:HLVX)

Jane Street Group LLC grew its position in HilleVax, Inc. (NASDAQ:HLVX) by 81.7% during the 3rd quarter, Holdings Channel.com reports. The firm owned 79,039 shares of the company’s stock after purchasing an additional 35,546 shares during the period. Jane Street Group LLC’s holdings in HilleVax were worth $139,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Rhumbline Advisers grew its holdings in HilleVax by 27.0% in the second quarter. Rhumbline Advisers now owns 42,658 shares of the company’s stock worth $617,000 after purchasing an additional 9,073 shares during the last quarter. Fred Alger Management LLC grew its holdings in HilleVax by 9.7% in the second quarter. Fred Alger Management LLC now owns 136,166 shares of the company’s stock worth $1,969,000 after purchasing an additional 12,044 shares during the last quarter. Maven Securities LTD purchased a new position in HilleVax in the second quarter worth $217,000. TD Asset Management Inc grew its holdings in HilleVax by 53.9% in the second quarter. TD Asset Management Inc now owns 54,236 shares of the company’s stock worth $784,000 after purchasing an additional 19,000 shares during the last quarter. Finally, BML Capital Management LLC purchased a new position in HilleVax in the third quarter worth $35,000. 86.42% of the stock is owned by hedge funds and other institutional investors.

HilleVax Trading Down 2.4 %

NASDAQ HLVX opened at $2.00 on Tuesday. The firm’s fifty day simple moving average is $1.94 and its two-hundred day simple moving average is $2.37. HilleVax, Inc. has a 12-month low of $1.55 and a 12-month high of $20.22. The firm has a market capitalization of $99.61 million, a P/E ratio of -0.65 and a beta of 0.75.

HilleVax (NASDAQ:HLVX) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.10). As a group, sell-side analysts predict that HilleVax, Inc. will post -2.64 earnings per share for the current fiscal year.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.